540 GAITHER ROAD, ROCKVILLE, MD
Reports Second Quarter 2026 Financial Results and Recent Business Updates
Board Appointment - Ron Philip Joins Avalo Therapeutics Board
Investor Presentation
Material Contracts, News
Reports First Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics Enters Underwriting Agreement for $350 Million Offering
Purchases Optional Milestone Buyout
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report